Mumbai, Oct, 16: Gujarat-based pharmaceutical company Zydus Cadila today said it had entered into a drug development and commercialisation alliance with Germany’s Pieris AG for a novel therapeutic molecule.
The molecule, called anticalin, is expected to be more effective in treating certain diseases because of its ability to penetrate deep into tumours.
In a statement, Zydus said the collaboration combined Pieris’ drug discovery and early development capabilities with its expertise in biologics development, regulatory affairs and biologics manufacturing.
Under the terms of the agreement, Zydus will take the lead in advancing anticalin drug candidates through formal pre-clinical development into the clinical phase. Zydus has been granted exclusive marketing rights in India and other emerging markets, while Pieris has exclusive marketing rights in the key developed markets.
The companies will explore out-licensing opportunities in Pieris’ territories, besides looking at sharing licensing revenues on “mutually agreed upon terms”.
Zydus added that the most advanced programme in the collaboration was PRS-110, a target which was increasingly becoming validated across a broad spectrum of tumours.
“Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus’s ongoing transformation into an innovation-led global healthcare provider and we are pleased to add anticalin to our novel biologics pipeline,” Zydus group chairman and managing director R. Patel said.
The tie-up is seen as part of Zydus’s plan to be a global healthcare provider with a robust product pipeline and achieving sales of over $3 billion by 2015, apart from being a research-based pharmaceutical company by 2020.
In biologics, Zydus has developed a pipeline of 17 biosimilar drugs (generic version of a biopharmaceutical drug) with six such drugs commercialised and others in clinical development.
Pieris CEO Stephen Yoder said the tie-up would allow the company to unlock value on a global scale in a cost-effective manner.